An outbreak of respiratory syncytial virus infection in hematopoietic stem cell transplantation outpatients: Good outcome without specific antiviral treatment

Transplant Infectious Disease

Volumn 15, Issue 1, 2013, Pages 42-48

  Mendes, E T ^a   Ramos, J ^a   Peixoto, D ^a   Dulley, F ^a   Alves, T ^a   Vilas Boas, L S ^a   Batista, M V ^a   Da Silva, D P ^b   Levin, A S ^a   Shikanai Yasuda, M A ^a   Costa, S F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b HOSPITAL BENEFICÊNCIA PORTUGUESA DE SÃO PAULO   (Brazil)

Author keywords

Hematopoietic stem cell transplantation; Outpatients; Respiratory syncytial virus

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; PREDNISONE;

ADULT; ANTIBIOTIC THERAPY; ANTIVIRAL THERAPY; ARTICLE; AUTUMN; CLINICAL ARTICLE; DEATH; EPIDEMIC; FEMALE; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMAN; INVASIVE ASPERGILLOSIS; LOWER RESPIRATORY TRACT INFECTION; LYMPHOCYTOPENIA; MALE; NEUTROPENIA; OUTCOME ASSESSMENT; OUTPATIENT; OUTPATIENT CARE; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL VIRUS INFECTION; RISK FACTOR; SCREENING;

ADOLESCENT; ADULT; AGED; ANTIVIRAL AGENTS; CHILD; CROSS INFECTION; DISEASE OUTBREAKS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MIDDLE AGED; NASAL LAVAGE FLUID; OUTPATIENTS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RISK FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84873464897     PISSN: 13982273     EISSN: 13993062     Source Type: Journal    
DOI: 10.1111/j.1399-3062.2012.00764.x     Document Type: Article

References (24)

1. Welliver RC. Pharmacotherapy of respiratory syncytial virus infection. Curr Opin Pharmacol 2010; 10: 289-293.
2. Khanna N, Widmer AF, Decker M, et al. Respiratory syncytial virus infection in patients with hematological diseases: single left study and review of the literature. Clin Infect Dis 2008; 46 (3): 402-412.
3. Machado CM, Vilas Boas LS, Mendes AVA, et al. Low mortality rates related to respiratory virus infections after bone marrow transplantation. Bone Marrow Transplant 2003; 31: 695-700.
4. Abdallah A, Rowland KE, Schepetiuk SK, To LB, Bardy P. An outbreak of respiratory syncytial virus infection in a bone marrow transplant unit: effect in engraftment and outcome of pneumonia without specific antiviral treatment. Bone Marrow Transplant 2003; 32: 195-203.
5. Smal TN, Casson A, Malak SF, et al. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 321-327.
6. Shah JN, Chemaly RF. Management of RSV infections in adult recipients of hematopoietic stem cell transplant: review of the literature. Blood 2011; 117 (10): 2755-2763.
7. Tomblyn M, Chiller T, Einsele H, et al. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. ASBMT. Biol Blood Marrow Transplant 2009; 15 (10): 1143-1238.
8. De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46 (12): 1813-1821.
9. de Fontbrune FS, Robin M, Porcher R, et al. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2007; 45 (8): 1019-1024.
10. Graham BS, Davis TH, Tang YW, Gruber WC. Immunoprophylaxis and immunotherapy of RSV-infected mice with RSV-specific immune serum. Pediatr Res 1993; 34 (2): 167-172.
11. Ljungman P, Ward KN, Crooks BN, et al. Respiratory virus infections after stem cell transplantation: a prospective study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2001; 28 (5): 479-484.
12. Crooks BN, Taylor CE, Turner AJ, et al. Respiratory viral infections in primary immune deficiencies: significance and relevance to clinical outcome in a single BMT unit. Bone Marrow Transplant 2000; 26 (10): 1097-1102.
13. Martino R, Porras RP, Rabella N, et al. Prospective study of the incidence, clinical features, and outcome of symptomatic upper and lower respiratory tract infections by respiratory viruses in adult recipients of hematopoietic stem cell transplants for hematologic malignancies. Biol Blood Marrow Transplant 2005; 11 (10): 781-796.
14. Whimbey E, Champlin RE, Englund JA, et al. Combination therapy with aerosolized ribavirin and intravenous immunoglobulin for respiratory syncytial virus disease in adult bone marrow transplant recipients. Bone Marrow Transplant 1995; 16: 393-399.
15. Roghmann M, Ball K, Erdman D, Lovchik J, Anderson LJ, Edelman R. Active surveillance for respiratory virus infections in adults who have undergone bone marrow and peripheral blood stem cell transplantation. Bone Marrow Transplant 2003; 32: 1085-1088.
16. Khushalani NI, Bakri FG, Wentling D, Brown K, Mohr A, Anderson B. Respiratory syncytial virus infection in the late bone marrow transplant period: report of three cases and review. Bone Marrow Transplant 2001; 27: 1071-1073.
17. Peck AJ, Corey L, Boeckh M. Pretransplantation respiratory syncytial virus infection: impact of a strategy to delay transplantation. Clin Infect Dis 2004; 39: 673-680.
18. Ghosh S, Champlin RE, Englund J, et al. Respiratory syncytial virus upper respiratory tract illnesses in adult blood and marrow transplant recipients: combination therapy with aerosolized ribavirin and intravenous immunoglobulin. Bone Marrow Transplant 2000; 25: 751-755.
19. Avetisyan G, Mattsson J, Sparrelid E, Ljungman P. Respiratory syncytial virus infection in recipients of allogeneic stem-cell transplantation: a retrospective study of the incidence, clinical features, and outcome. Transplantation 2009; 88 (10): 1222-1226.
20. Chemaly RF, Ghosh S, Bodey GP, et al. Respiratory viral infections in adults with hematologic malignancies and human stem cell transplantation recipients: a retrospective study at a major cancer left. Medicine 2006; 85 (5): 278-287.
21. McColl MD, Corser RB, Bremner J, Chopra R. Respiratory syncytial virus infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. Bone Marrow Transplant 1998; 21 (4): 423-425.
22. Kassis C, Champlin RE, Hachem RY, et al. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab. Biol Blood Marrow Transplant 2010; 16 (9): 1265-1271.
23. Ottolini MG, Porter DD, Hemming VG, Zimmerman MN, Schwab NM, Prince GA. Effectiveness of RSVIG prophylaxis and therapy of respiratory syncytial virus in an immunosuppressed animal model. Bone Marrow Transplant 1999; 24 (1): 41-45.
24. Lavergne V, Ghannoum M, Weiss K, Roy J, Be'liveau C. Successful prevention of respiratory syncytial virus nosocomial transmission following an enhanced seasonal infection control program. Bone Marrow Transplant 2011; 46: 137-142.